A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement
| Autor: | Manoj Kumar Pandre, Shama Shaik, Sayan Mitra, Prasad Yadlapalli, Veera Venkata Valluri Satya Pratap, Mahesh Yanamandra |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
animal structures Drug Evaluation Preclinical Biophysics Enzyme-Linked Immunosorbent Assay Tropomyosin receptor kinase A Biochemistry Cell Line Mice Structure-Activity Relationship 03 medical and health sciences 0302 clinical medicine Western blot medicine Animals Humans Phosphorylation Receptor trkA Kinase activity Protein Kinase Inhibitors Molecular Biology Cell Proliferation Dose-Response Relationship Drug medicine.diagnostic_test Chemistry Kinase Cell Biology Molecular biology Fusion protein 030104 developmental biology nervous system Protein kinase domain 030220 oncology & carcinogenesis Trk receptor |
| Zdroj: | Analytical Biochemistry. 545:78-83 |
| ISSN: | 0003-2697 |
| Popis: | Tropomyosin-related kinase A (TRKA) fusion was originally detected in colorectal carcinoma that had resulted in expression of the oncogenic chimeric protein TPM3-TRKA. Lately, many more rearrangements in TRK family of kinases generating oncogenic fusion proteins have been identified. These genetic rearrangements usually result in fusion of cytoplasmic kinase domain of TRK to another gene of interest resulting in constitutive kinase activity. Estimation of TRK inhibitor potency in a cellular context is required for drug discovery programs and is measured by receptor phosphorylation levels upon compound administration. However, since a large chunk of the TRK protein is lost in this rearrangement, it's difficult to set up sandwich ELISA for detection of receptor phosphorylation in any cell assay harboring these fusion proteins. In order to address this issue, we developed a novel and robust in-cell ELISA method which quantifies the phosphorylation of TRK kinase (Tyr 674/675) within the KM12 cells. This cell based method is more versatile & economical than conventional ELISA using engineered overexpressing cell line and/or western blot methods. Performance reliability & robustness for the validated assay were determined by %CV and Z factor in assays with reference molecule larotrectinib. This in-cell ELISA method can be used with any TRKA rearranged oncogenic fusion cell type and can be extended to other TRK isoforms as well. We have used this assay to screen novel molecules in KM12 cells and to study pharmacodynamic properties of compounds in TRKA signaling. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect